Become a member

About us

APRA is an interdisciplinary academic association for university students and researchers, focusing on psychedelic substances (e.g. LSD, psilocybin) for their therapeutic effects or scientific value. We aim to provide high quality education about developments in psychedelic science, destigmatize research in this field and promote the start of an interdisciplinary research effort within the Amsterdam institutions.

Read more

Events

We organise both local and online events for APRA members. Our academic events focus on all psychedelics-related topics, adopting an interdisciplinary scientific approach. Our social events  allow you to connect with others with similar interests, in a less formal environment.

Explore

Events

We organize both local and online events for APRA members. Our academic events focus on all psychedelics-related topics, adopting an interdisciplinary scientific approach. Our social events  allow you to connect with others with similar interests, in a less formal environment.

Explore

Ethnoracial inclusion in clinical trials of psychedelics

Despite increasing awareness of the need for diversity in clinical research, psychedelic studies have shown limited ethnoracial representation. A systematic review of 39 studies on psychedelic treatments for psychiatric or substance use disorders, published between...
Read More

Participate: The role of memories in psychedelic experience

Are you planning to take a psychedelic in the next few weeks in any context? Please join the AutoPsy study to help us better understand the role of memories in psychedelic experiences! For more information and to participate in this study,...
Read More

MAPS announces submission of New Drug Application to the FDA for MDMA-assisted therapy for PTSD

MAPS Public Benefit Corporation (MAPS PBC) has reached a significant milestone by submitting a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for MDMA (midomafetamine capsules) in conjunction with psychological intervention for the treatment...
Read More

Pharmahuasca passes its first clinical test

This study by Dornbierer et al. (2023) explores alternative administration methods for ayahuasca's principle psychoactive components, specifically DMT and harmine. It appears to show promising implications for the future of clinical ayahuasca research. By developing a...
Read More

Trait mindfulness and personality characteristics in a microdosing ADHD sample

This study explores the effects of microdosing psychedelics on mindfulness and personality traits in adults diagnosed with attention deficit hyperactivity disorder (ADHD) or experiencing severe ADHD symptoms. The research, conducted over 4 weeks with 233 participants,...
Read More

Extended difficulties following the use of psychedelic drugs

A recently published study by Evans et al. (2023) has investigated long-term psychological distress following the use of psychedelic drugs. Long-term adverse experiences following psychedelic use can persist for weeks, months, or even years, and are relatively...
Read More

First clinical trial results on psilocybin for anorexia nervosa

Earlier this week, the first-ever clinical trial results of a study investigating the effects of psilocybin on females with anorexia nervosa (AN) were published in Nature Medicine. It concerns a phase I open-label feasibility study (N=10) which investigated the...
Read More

LSD couples study at Maastricht University

The University of Maastricht has started a study regarding the effects of LSD (lysergic acid diethylamide) on brain activity and social behavior. For this study, they are looking for healthy volunteers (18-35 years old) in a relationship who have previously used a...
Read More

Watch now: Dr. Daan Oostveen – Psychedelic Humanities

Watch the recording of our lecture by Dr. Daan Oostveen on psychedelic humanities. The video is now available on the APRA YouTube channel. Be sure to check out our previous videos and subscribe to the channel! Over the past decade, great results have been presented to...
Read More

Apply now for a psilocybin neuroimaging study in Amsterdam!

A study by APRA founder Marco Aqil at the Spinoza Center for Neuroimaging is investigating the effects of psilocybin on visual processing with a 7-Tesla fMRI scanner. This is the first-ever psychedelic neuroimaging study in Amsterdam and one of the first psychedelic...
Read More

Join our community

Looking to expand your knowledge of the psychedelic field and be part of our community? Consider becoming a member. With benefits ranging from networking opportunities, academic resources, discounts on events and our members-only newsletter, membership offers many opportunities for growth and connection. 

Join us

Join our community

Looking to expand your knowledge of the psychedelic field and be part of our community? Consider becoming a member. With benefits ranging from networking opportunities, academic resources, discounts on events and our members-only newsletter, membership offers many  opportunities for growth and connection. 

Join us